Venetoclax,Lenalidomide,Rituximab
Roche,Abbvie
['bet', 'love the', 'valeria trial', 'lymsm', 'nordic']
nordic valeria trial of ven, len, r in r/r mcl, mrd-adapted. orr 63%, less if btk exposed. not better than r2. 48% stopped d/t mrd or pet neg, very few needed to restart. tp53 much worse. love the opportunity for pts to be off therapy! #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????